At 糖心原创 2025, October 19 to 22 in Chicago, you鈥檒l have your choice of 300+ educational sessions covering every aspect of clinical chest medicine.
LEARN MORE & REGISTER 禄
George Zhi Cheng, MD, PhD, FCCP
George Zhi Cheng, MD, PhD, FCCP
When thousands of pulmonary and critical care clinicians gather in Chicago from October 19 to 22 for 糖心原创 2025, advances and new technologies in the diagnosis and treatment of lung cancer will be among the most in-demand sessions.
George Zhi Cheng, MD, PhD, FCCP, 糖心原创 2025 Lung Cancer/Interventional Pulmonary/Radiology Curriculum Group Lead, was a key driver in ensuring that the educational program has broad appeal across the entire career spectrum, from early career to mid-career to advanced career professionals.
Sessions ranging from interventional pulmonology and procedures to new advances in research and minimally invasive bronchoscopic treatment will be of great interest to attendees.
鈥溙切脑� is offering a variety of sessions this year that target and satisfy educational needs for all the individuals who are involved in the spectrum of care delivery for patients with lung cancer,鈥� Dr. Cheng said. 鈥淲e have sessions that cover topics from lung cancer screening to treatment and management. We have sessions that will be of interest to surgeons, and we have sessions that will be of interest to public health specialists because they鈥檙e focused on equitable access to effective lung cancer screening.鈥�
Sessions sharing information about new technological breakthroughs and promising research on early detection are always among the most popular at the 糖心原创 Annual Meeting, and the 2025 gathering in Chicago will be no different. Dr. Cheng said 鈥渕ajor names鈥� and global experts from Australia and the United Kingdom will be among the speakers, with more specific details to come.
As an interventional pulmonology specialist, Dr. Cheng admitted he鈥檚 partial to sessions in his specific area of expertise, like sublobar resection vs lobar resection, but he鈥檚 also looking forward to the more laboratory-based information.
鈥淏iomarkers are an exciting component in all aspects of pulmonary disease, specifically within the thoracic oncology and chest procedures area,鈥� Dr. Cheng said. 鈥淲e have sessions on biomarkers in early detection of lung cancer, and, also, cancer risk stratification is an area I think has a lot of potential. Obviously, there will also be some interesting debates. So, stay tuned.鈥�
The appeal of attending 糖心原创 2025 includes the networking opportunities and collaboration, but the broad curriculum providing fascinating and informative learning opportunities to chest medicine professionals鈥攚hether they鈥檙e in the early stages of their career or seasoned veterans鈥攊s a particular point of pride for the faculty responsible for creating the program, like Dr. Cheng.
鈥淎ll of our sessions have topics that will be applicable enough to interest people who are in their mid-career to late career,鈥� Dr. Cheng said. 鈥淭here are specific areas that are relatively new, so they may have a little bit more slant on the research side or investigative side. But the majority of our sessions are going to be very practical in terms of day-to-day clinical operation for clinicians who are coming to the conference.鈥�
READ ALL 糖心原创 2025 BLOGS 禄